DEERFIELD, Ill., June 22, 2009 - Walgreens (NYSE, NASDAQ: WAG) today announced earnings and sales results for the third quarter of fiscal year 2009. Net earnings for the quarter ending May 31 were $522 million or 53 cents per share (diluted), including an impact of 6 cents in costs and 6 cents in savings associated with the company's Rewiring for Growth and Customer Centric Retailing (CCR) initiatives. This reflects an 8.8 percent decrease from $572 million or 58 cents per share (diluted) in the same quarter a year ago. Net earnings for the first nine months of fiscal 2009 were $1.57 billion or $1.58 per share (diluted), including an impact of 13 cents in costs and 9 cents in savings associated with the Rewiring for Growth and CCR initiatives. This reflects an 8.4 percent decrease from last year's $1.71 billion or $1.72 per share (diluted). Cash flow from operations for the quarter increased 54 percent over last year's quarter to $1.5 billion, driven in large...

DEERFIELD, Ill., Dec. 22, 2008 - Walgreens (NYSE, NASDAQ: WAG) today announced earnings and sales results for the first quarter of fiscal year 2009. Net earnings for the quarter ended Nov. 30 decreased 10.4 percent to $408 million or 41 cents per share (diluted), from $456 million or 46 cents per share (diluted) in the same quarter a year ago. Sales for the first quarter increased 6.6 percent to a record $14.9 billion, while sales in comparable stores (those open more than a year) rose 1.7 percent in the quarter. Prescription sales, which accounted for 66 percent of sales in the quarter, climbed 6.2 percent. Prescription sales in comparable stores rose 2.6 percent in the quarter. The number of prescriptions filled in comparable stores was virtually flat, although prescriptions were up 1.5 percent when adjusted for more patients filling 90-day prescriptions versus 30-day. U.S. retail prescription volume (excluding Walgreens) decreased 0.5 percent during the sa...

DEERFIELD, Ill., Sept. 12, 2008 – Walgreens (NYSE, NASDAQ: WAG) today proposed to acquire all of the outstanding shares of Longs Drug Stores Corporation (NYSE: LDG) for $75 per share in cash for a total purchase price of approximately $3 billion including the assumption of debt. The offer, which is subject to standard regulatory approvals and the completion of due diligence, represents a $3.50 per share premium over the cash purchase price to be paid to Longs shareholders under the proposed acquisition by CVS/Caremark Corporation (NYSE: CVS) announced on Aug. 12.As a result of this transaction, Walgreens would acquire Longs' retail drugstores in California, Hawaii, Nevada and Arizona, as well as its RxAmerica, LLC subsidiary, which offers prescription benefits management (PBM) services. The combination would provide substantial strategic and financial benefits, including strengthening Walgreens ability to serve customers in fast growing markets and broade...